Case report: mRNA-1273 COVID-19 vaccine-associated myopericarditis: Successful treatment and re-exposure with colchicine

INTRODUCTION: Vaccine-induced myocarditis is a rare complication of messenger RNA (mRNA) COVID-19 vaccines. CASE PRESENTATION: We report a case of acute myopericarditis in a recipient of allogeneic hematopoietic cells following the first dose of the mRNA-1273 vaccine and the successful administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Valore, Luca, Junker, Till, Heilmann, Eva, Zuern, Christine S., Streif, Matthias, Drexler, Beatrice, Arranto, Christian, Halter, Jörg P., Berger, Christoph T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149711/
https://www.ncbi.nlm.nih.gov/pubmed/37139123
http://dx.doi.org/10.3389/fcvm.2023.1135848
Descripción
Sumario:INTRODUCTION: Vaccine-induced myocarditis is a rare complication of messenger RNA (mRNA) COVID-19 vaccines. CASE PRESENTATION: We report a case of acute myopericarditis in a recipient of allogeneic hematopoietic cells following the first dose of the mRNA-1273 vaccine and the successful administration of a second and third dose while on prophylactic treatment with colchicine to successfully complete the vaccination. CONCLUSION: Treatment and prevention of mRNA-vaccine-induced myopericarditis represent a clinical challenge. The use of colchicine is feasible and safe to potentially reduce the risk of this rare but severe complication and allows re-exposure to an mRNA vaccine.

Ejemplares similares